title: Comment on Rickels et al. Intranasal Glucagon for Treatment of Insulin-Induced Hypoglycemia in Adults With Type 1 Diabetes: A Randomized Crossover Noninferiority Study. Diabetes Care 2016;39:264-270.
authors.affiliation: Division of Endocrinology, Diabetes & Metabolism, Department of Internal Medicine, University of South Carolina School of Medicine, and Wm. Jennings Bryan Dorn VA Medical Center, Columbia, SC andres.munoz@va.gov.
authors.forename: Andres Julian
authors.initials: AJ
authors.lastname: Munoz
authors.affiliation: Division of Endocrinology, Diabetes & Metabolism, Department of Internal Medicine, University of South Carolina School of Medicine, and Wm. Jennings Bryan Dorn VA Medical Center, Columbia, SC.
authors.forename: Sunitha
authors.initials: S
authors.lastname: Girish
authors.affiliation: Division of Endocrinology, Diabetes & Metabolism, Department of Internal Medicine, University of South Carolina School of Medicine, and Wm. Jennings Bryan Dorn VA Medical Center, Columbia, SC South University School of Pharmacy, Columbia, SC.
authors.forename: Marquita B
authors.initials: MB
authors.lastname: Winder
mesh_terms: D000328:Adult; D001786:Blood Glucose; D003922:Diabetes Mellitus, Type 1; D005934:Glucagon; D006801:Humans; D007003:Hypoglycemia; D007004:Hypoglycemic Agents; D007328:Insulin
chemical_list: D001786:Blood Glucose; D007004:Hypoglycemic Agents; D007328:Insulin; D005934:Glucagon